Cardiogenesis Corporation to Report Third Quarter 2009 Results on November 10th

IRVINE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation
(Pink Sheets: CGCP), announced that the company will release results for its
third quarter ended September 30, 2009 after market close on Tuesday, November
10, 2009. The company also said that Executive Chairman Paul J. McCormick and
Senior Vice President and Chief Financial Officer William R. Abbott will host
an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m.
Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio web
broadcast via the Internet at www.cardiogenesis.com and will also be available
by dialing (866) 362-4666. The participant passcode is 90770475. The call
will be archived on the company's web site and will be available for playback
for seven days beginning shortly after the live webcast.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of
cardiovascular disease and is a leader in devices that stimulate cardiac
angiogenesis. The company's market leading Holmium:YAG laser system and
disposable fiber-optic accessories are used to perform a FDA-cleared surgical
procedure known as Transmyocardial Revascularization (TMR) to treat patients
suffering from angina. Surgical products and accessories for the
Cardiogenesis TMR procedure, which are marketed in the U.S. and around the
world, have been shown to reduce angina and improve the quality of life in
patients with coronary artery disease.

For more information on the company and its products, please visit the
Cardiogenesis company website at http://www.cardiogenesis.com or the direct to
patient website at http://www.heartofnewlife.com.

Cardiogenesis Corporation, +1-949-420-1800
http://www.cardiogenesis.com

SOURCE Cardiogenesis Corporation

William R. Abbott, Senior Vice President and Chief Financial Officer of
Cardiogenesis Corporation, +1-949-420-1800